MARKET

LLY

LLY

Lilly Eli & Co
NYSE
732.20
-13.49
-1.81%
After Hours: 724.69 -7.51 -1.03% 19:58 04/24 EDT
OPEN
752.64
PREV CLOSE
745.69
HIGH
752.64
LOW
728.79
VOLUME
2.13M
TURNOVER
0
52 WEEK HIGH
800.78
52 WEEK LOW
367.60
MARKET CAP
696.15B
P/E (TTM)
126.21
1D
5D
1M
3M
1Y
5Y
LLY vs. JNJ: Which Big Pharma Stock Is Better?
I evaluated two big pharma stocks, Eli Lilly and Johnson & Johnson, using TipRanks’ Comparison Tool. Shares of Eli Lilly have surged 26% year-to-date and are up 92% over the last 12 months. A neutral view for Eli Lilly suggests a bullish view for Johnson and Johnson. Eli Lilly is trading at a much higher valuation than JNJ.
TipRanks · 2h ago
Will Higher Keytruda Sales Drive Merck's Q1
NASDAQ · 3h ago
Plaintiffs' lawyers chosen to lead Ozempic litigation
Plaintiffs' lawyers chosen to lead Ozempic litigation. Lawsuits allege companies failed to warn of harsh side effects associated with diabetes and weight loss drugs. A judge appointed eight plaintiffs' lawyers to leadership roles in federal mass tort litigation. The companies have said the claims are meritless.
Reuters · 9h ago
Novo Nordisk comes under Senate probe over pricing for weight loss drugs
Danish drugmaker Novo Nordisk comes under Senate probe over pricing for weight loss drugs. Sen. Bernie Sanders says the company charges 'outrageously high prices' for the popular drug semaglutide in the U.S. The Senate committee wants to know how the company prices the drug.
Seeking Alpha · 10h ago
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senator Bernie Sanders wants to investigate Novo Nordisk A/S’s pricing strategies for diabetes and obesity medications. The Senate Committee on Health, Education, Labor, and Pensions is looking into the company's pricing discrepancies. Study suggests that Medicare may cover drugs approved for obesity and heart conditions.
Benzinga · 11h ago
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Madrigal Pharmaceuticals, Inc. Recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035. The company will have to overcome two challenges to maintain its "first mover" advantage in the market. Madrigal has to manage the launch of Rezdiffra and keep an eye on future competitors.
Seeking Alpha · 12h ago
MEDIA-US Senate committee investigates Ozempic and Wegovy costs - NYT
Reuters · 13h ago
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
NASDAQ · 13h ago
More
About LLY
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.

Webull offers Eli Lilly And Co stock information, including NYSE: LLY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LLY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LLY stock methods without spending real money on the virtual paper trading platform.